BR0107862A - Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico - Google Patents
Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmicoInfo
- Publication number
- BR0107862A BR0107862A BR0107862-3A BR0107862A BR0107862A BR 0107862 A BR0107862 A BR 0107862A BR 0107862 A BR0107862 A BR 0107862A BR 0107862 A BR0107862 A BR 0107862A
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- preparation
- hydroxamic acid
- inhibitors
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
"MéTODO PARA A PREPARAçãO DE DERIVADOS DO áCIDO ALFA-SULFONIL HIDROXâMICO". Compostos da fórmula (I) que podem ser importantes como inibidores de metaloproteinase de matriz (MMP) e de enzima de conversão de TNF-alfa (TACE), inibidores de fosforodiesterase, inibidores de renina, antitrombóticos e inibidores de 5-lipoxigenase são preparados através dos métodos da presente invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49297500A | 2000-01-27 | 2000-01-27 | |
PCT/US2001/002669 WO2001055112A1 (en) | 2000-01-27 | 2001-01-25 | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0107862A true BR0107862A (pt) | 2002-11-05 |
Family
ID=23958375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0107862-3A BR0107862A (pt) | 2000-01-27 | 2001-01-25 | Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1252143A1 (pt) |
JP (1) | JP2003520852A (pt) |
CN (1) | CN1400968A (pt) |
AR (1) | AR031550A1 (pt) |
AU (1) | AU2001233034A1 (pt) |
BR (1) | BR0107862A (pt) |
CA (1) | CA2398561A1 (pt) |
MX (1) | MXPA02007291A (pt) |
WO (1) | WO2001055112A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4510384B2 (ja) * | 2001-05-23 | 2010-07-21 | 田辺三菱製薬株式会社 | 骨折治癒促進用組成物 |
DK1432431T3 (en) | 2001-10-04 | 2017-07-10 | Genetics Inst Llc | Methods and compositions for modulating interleukin-21 activity |
WO2003106381A2 (en) | 2002-06-12 | 2003-12-24 | Exelixis, Inc. | Human adam-10 inhibitors |
EP1577299A1 (en) * | 2002-12-26 | 2005-09-21 | Carna Biosciences Inc. | Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient |
BRPI0408315A (pt) | 2003-03-14 | 2006-03-07 | Wyeth Corp | anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico |
JP2008520717A (ja) | 2004-11-19 | 2008-06-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 多発性硬化症についての処置 |
BRPI0516383A (pt) * | 2004-12-21 | 2008-09-02 | Serono Lab | derivados cìclicos de sulfonil amino e o uso dos mesmos |
CA2597945C (en) | 2005-02-17 | 2016-07-12 | Biogen Idec Ma Inc. | Treating neurological disorders |
GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-22(il-22)之抗體及其用途 |
WO2008019284A1 (en) * | 2006-08-04 | 2008-02-14 | Decode Genetics Ehf | Phenoxymethylalkyne inhibitors of lta4h for treating inflammation |
JP2010529999A (ja) | 2007-06-14 | 2010-09-02 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗体製剤 |
EP2070899A1 (en) * | 2007-12-14 | 2009-06-17 | F. Hoffmann-La Roche Ag | Deprotection of N-BOC compounds |
EP2558499B1 (en) | 2010-04-16 | 2017-04-12 | Biogen MA Inc. | Anti-vla-4 antibodies |
DK3575792T3 (da) | 2011-05-31 | 2023-02-27 | Biogen Ma Inc | Fremgangsmåde til vurdering af risiko for pml |
US10955422B2 (en) | 2014-02-27 | 2021-03-23 | Biogen Ma, Inc. | Method of assessing risk of PML |
US20210238289A1 (en) | 2018-06-04 | 2021-08-05 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
AU2019352741A1 (en) | 2018-10-04 | 2021-05-06 | Assistance Publique-Hôpitaux De Paris (Aphp) | EGFR inhibitors for treating keratodermas |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04295B1 (et) * | 1997-02-27 | 2004-06-15 | American Cyanamid Company | N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül-, -sulfinüül- või-sulfonüül-)-3-asendatud-alküülamiidid, -arüülamiidid või -heteroarüülamiididkui maatriksmetalloproteinaasi inhibiitorid |
GEP20022797B (en) * | 1998-02-19 | 2002-09-25 | American Cyanamid Co | N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors |
US6358980B1 (en) * | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6583299B1 (en) * | 1999-05-20 | 2003-06-24 | G.D. Searle & Co. | α-amino-β-sulfonyl hydroxamic acid compounds |
-
2001
- 2001-01-25 JP JP2001555054A patent/JP2003520852A/ja active Pending
- 2001-01-25 EP EP01905121A patent/EP1252143A1/en not_active Withdrawn
- 2001-01-25 MX MXPA02007291A patent/MXPA02007291A/es unknown
- 2001-01-25 WO PCT/US2001/002669 patent/WO2001055112A1/en not_active Application Discontinuation
- 2001-01-25 BR BR0107862-3A patent/BR0107862A/pt not_active IP Right Cessation
- 2001-01-25 AU AU2001233034A patent/AU2001233034A1/en not_active Abandoned
- 2001-01-25 CA CA002398561A patent/CA2398561A1/en not_active Abandoned
- 2001-01-25 CN CN01804199A patent/CN1400968A/zh active Pending
- 2001-01-26 AR ARP010100352A patent/AR031550A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2398561A1 (en) | 2001-08-02 |
AR031550A1 (es) | 2003-09-24 |
WO2001055112A1 (en) | 2001-08-02 |
EP1252143A1 (en) | 2002-10-30 |
MXPA02007291A (es) | 2002-11-29 |
JP2003520852A (ja) | 2003-07-08 |
AU2001233034A1 (en) | 2001-08-07 |
CN1400968A (zh) | 2003-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0107862A (pt) | Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico | |
BR112022015945A2 (pt) | Microrganismo que compreende lyse variante e método de produção de l-aminoácido que usa o mesmo | |
BR0114576A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto | |
NO20051788L (no) | Hydantoinderivater og deres anvendelse som TACE-inhibitorer | |
AU2003282920A8 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
BR0114917A (pt) | Inibidores de pirimidina-2,4,6-triona metaloproteinase | |
TR200401739T4 (tr) | Persikuinnin, üretimi ve ilaç olarak kullanımı için bir işlem | |
UY26285A1 (es) | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas | |
DK0927161T3 (da) | Substitueret cyklisk amin-metalloproteaseinhibitorer | |
NO20024402D0 (no) | Cykliske <beta>-aminosyrederivater som inhibitorer av matriksmetalloproteaser og TNF-<alfa> | |
PT1084104E (pt) | Inibidores da sintase de oxido nitrico | |
AU2002357312A1 (en) | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases | |
WO2004032846A3 (en) | Triazolone and triazolethione derivatives | |
EA200100804A1 (ru) | Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз | |
TR200002446T2 (tr) | Fosfolipaz enzimlerinin inhibitörleri | |
EA200101085A1 (ru) | Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз | |
BRPI0206433B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
NZ524559A (en) | 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | |
BR0315662A (pt) | Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona | |
WO2001096606A3 (en) | Identification of genes and compounds for treatment of cancer | |
NO20032822D0 (no) | Fremgangsmåte for konsentrering av brukt syre | |
BR9713207A (pt) | Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz | |
WO2001091796A8 (en) | Methods, compounds and compositions for treating gout | |
BRPI0411308A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
DK1165491T3 (da) | LTA4-hydrolase-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: WYETH HOLDINGS CORPORATION (US) Free format text: ALTERADO DE: AMERICAN CYANAMID COMPANY |
|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016DE 25/08/2009 |